AmbioPharm Inc., a biopharmaceutical manufacturer that produces peptides for drug companies, is expanding its North Augusta operations, creating 100 new jobs in five years, according to a news release from the company.
The expansion also is projected to bring $18 million of new capital investment, according to the release. AmbioPharm will add two freestanding buildings totaling 50,000 square feet and purchase additional equipment.
Hiring for the new positions is projected to begin in the second quarter of 2018. Interested applicants can find more information at ambiopharm.com.
The state Coordinating Council for Economic Development has approved job development credits related to this project.
“AmbioPharm is our city’s best kept secret,” Mayor Bob Pettit said. “(The company’s) continued growth and expansion are impressive. I’m glad it calls North Augusta home.”
In 2007, AmbioPharm moved into the former UCB Bioproducts facility in the North Augusta Industrial Park at 1024 Dittman Court, establishing its company headquarters and downstream manufacturing operations in a 10,000-square-foot facility.
Peptides are important ingredients in drugs for diabetes, cancer indications, cardiovascular disease, anti-HIV and gastric issues.
About 120 employees work at the North Augusta lab, making peptides from a solid product that is developed at the company’s China facility.
Once sent to the local site, the material is dissolved into a liquid, placed into a lyophilizer, or large freeze-dryer, and converted into a powder. The peptide is then shipped to another manufacturing facility where the process of making the drug is completed, Geiger said.
Most of the peptides produced at the facility are used in clinical applications, while others are used to develop generic drugs for products coming off a patent.